Big Patent Expirations of 2010

While the much-talked-about patent cliff won't hit until 2011, 2010 will still see patent expirations of some of the industry's blockbuster drugs. Teva, Apotex, Mylan and a slew of other generic drugmakers will have a chance to put a dent in the sales of a number of brand meds this year--including Flomax and Aricept. Lipitor, whose basic patent expires this year, doesn't face competition until 2011 because of Pfizer's deal with Ranbaxy, the first-filer. It's still included in the following list, which has a number of top-selling drugs.

Our 2010 patent expiration list also includes drugs whose patent actually expires, but managed to get a six-month extension due to pediatric exclusivity. Report

1. Cozaar/Hyzaar - Merck
2. Lipitor - Pfizer
3. Flomax - Boehringer Ingelheim
4. Arimidex - AstraZeneca
5. Climara - Bayer HealthCare
6. Aricept - Aricept
7. Invirase - Roche
8. Hycamtin - GlaxoSmithKline
9. Protonix - Pfizer
10. Levaquin - Levaquin


Suggested Articles

Merck KGaA has big plans for a site in Switzerland where it intends to knit together biologics development and manufacturing. 

Biocon’s key biosimilars plant in Bengaluru, India, has gotten mixed reviews from the FDA and has now received a Form 483 with five observations.

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?